As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that ...

A growing concern in Japan, but there is something new on the horizon. | Japan faces a growing "Drug Loss" issue, but ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...

After threatening to impose “25% or higher” tariffs on foreign-made pharmaceuticals along with automobiles and semiconductors ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...